Travere Therapeutics (TVTX) Gains from Investment Securities (2013 - 2023)

Travere Therapeutics' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $1.8 million for Q2 2023.

• Quarterly Gains from Investment Securities fell 62.5% year-over-year to $1.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $570000.0 (down 96.2% YoY) and the FY2022 annual result came in at $15.0 million, down 32.59% from the prior year.
• Gains from Investment Securities was $1.8 million for Q2 2023 at Travere Therapeutics, up from -$2.3 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $13.9 million in Q3 2021 and bottomed at -$11.5 million in Q4 2019.
• A 5-year average of $1.2 million and a median of $404500.0 in 2019 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2020 — Gains from Investment Securities jumped 826.43% — and 2022, when it tumbled 124.16%.
• Travere Therapeutics' Gains from Investment Securities stood at -$11.5 million in 2019, then soared by 81.37% to -$2.1 million in 2020, then rose by 18.65% to -$1.7 million in 2021, then dropped by 24.2% to -$2.2 million in 2022, then jumped by 185.15% to $1.8 million in 2023.
• Business Quant data shows TVTX's Gains from Investment Securities at $1.8 million in Q2 2023, -$2.3 million in Q1 2023, and -$2.2 million in Q4 2022.